Zhao Li-Ping, Xue Cong, Zhang Jian-Wei, Hu Zhi-Huang, Zhao Yuan-Yuan, Zhang Jing, Huang Yan, Zhao Hong-Yun, Zhang Li
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangdong, People's Republic of China.
Chin J Cancer. 2012 Oct;31(10):476-83. doi: 10.5732/cjc.012.10029. Epub 2012 Jun 6.
Gemcitabine has high activity against nasopharyngeal carcinoma (NPC). The level of ribonucleotide reductase subunit M1 (RRM1) expression is closely related to the efficacy of gemcitabine on non-small cell lung cancer and pancreatic cancer. However, the expression of RRM1 and its association with sensitivity to gemcitabine-based chemotherapy in advanced NPC is not known. In this study, we retrospectively collected 48 formalin-fixed, paraffin-embedded NPC tissues to evaluate the expression of RRM1 using immunohistochemistry. All patients were diagnosed and treated with gemcitabine-based chemotherapy at Sun Yat-sen University Cancer Center. RRM1 expression was positive in 17(35%) patients. RRM1 expression was not associated with sex, age, performance status, WHO histological type, number of distant metastases, previous treatment, or cycles of gemcitabine-based chemotherapy(P> 0.05). The progression-free survival of the RRM1-positive group was shorter than that of the RRM1-negative group (5 months vs. 7 months, P = 0.036), and the response rate of the RRM1-positive group was somewhat lower than that of the RRM1-negative group (51.6% vs. 35.3%, P = 0.278). There was no significant difference in median survival between the RRM1-positive and RRM1-negative groups (22 months vs. 19 months, P = 0.540). Our results show that RRM1-negative expression is related with longer progression-free survival in advanced NPC patients treated with gemcitabine-based regimens.
吉西他滨对鼻咽癌（NPC）具有高活性。核糖核苷酸还原酶亚基M1（RRM1）的表达水平与吉西他滨对非小细胞肺癌和胰腺癌的疗效密切相关。然而，在晚期鼻咽癌中RRM1的表达及其与基于吉西他滨化疗敏感性的关联尚不清楚。在本研究中，我们回顾性收集了48例福尔马林固定、石蜡包埋的鼻咽癌组织，采用免疫组织化学法评估RRM1的表达。所有患者均在中山大学肿瘤防治中心接受基于吉西他滨的化疗诊断和治疗。17例（35%）患者RRM1表达呈阳性。RRM1表达与性别、年龄、体能状态、WHO组织学类型、远处转移数量、既往治疗或基于吉西他滨化疗的周期均无关联（P>0.05）。RRM1阳性组的无进展生存期短于RRM1阴性组（5个月对7个月，P = 0.036），且RRM1阳性组的缓解率略低于RRM1阴性组（51.6%对35.3%，P = 0.278）。RRM1阳性组和RRM1阴性组的中位生存期无显著差异（22个月对19个月，P = 0.540）。我们的结果表明，在接受基于吉西他滨方案治疗的晚期鼻咽癌患者中，RRM1阴性表达与更长的无进展生存期相关。
